Purchase this article with an account.
Sandeep Grover, Jayson Edwards; Macular Findings in Retinitis Pigmentosa By Spectral-Domain OCT (Spectralis). Invest. Ophthalmol. Vis. Sci. 2012;53(14):5210.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Macular lesions in retinitis pigmentosa (RP) include foveal atrophy, cystic foveal changes and epiretinal membranes (ERM). Earlier studies have documented these changes based on clinical examination and fluorescein angiography. Since spectral-domain optical coherence tomography (SD-OCT) gives us valuable information about the retinal structure, this study was done to better define the incidence of these macular changes in RP based on the SD-OCT scans.
All patients with different inheritance patterns of RP, who underwent SD-OCT (Spectralis, Heidelberg Engineering, Germany) macular scans were included in the study. Based on previously published OCT normative criteria, ‘foveal thinning’ was defined as the central subfield thickness (CSF) measuring 225 microns or less. Conversely, ‘foveal thickening’ was defined as CSF beingmore than 315 microns. Other findings identified on SD-OCT scans were presence of cystic macular changes, ERM’s - foveal and extrafoveal, and macular holes.
94 eyes of 48 patients with RP were included in the study. Of the 48 patients, 17 (35.4%) had foveal thinning, 16 (33.3%) had cystic macular changes and/or foveal thickening and 33 (68.8%) had epiretinal membranes in at least one eye. Of the 94 eyes, 31 (33%) had foveal thinning, 25 (26.6%) had cystic macular changes and/or foveal thickening and 52(55.3%) had ERM in at least one eye. Two patients (3 eyes) had macular holes.
This study shows a definite higher incidence of macular changes in patients with RP as identified by SD-OCT. This study provides a deeper insight into the pathogenesis of some of these macular changes that can affect the central vision in these patients. Also this study helps to define the prognosis in these patients and these data will be helpful in defining criteria for forthcoming treatment trials.
This PDF is available to Subscribers Only